Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Sensus Healthcare (SRTS – Research Report). The associated price target remains the same with $12.00.
Yi Chen’s rating is based on the promising clinical outcomes of Sensus Healthcare’s SRT-100 in managing keloids. A recent study published in the Annals of Plastic Surgery demonstrated that the combination of surgical excision with adjuvant Superficial Radiation Therapy (SRT) significantly reduced keloid recurrence, with no recurrences observed in the patients studied over a follow-up period exceeding six months. This outcome is particularly noteworthy when compared to traditional treatments like corticosteroid injections and cryotherapy, which often result in inconsistent outcomes and higher recurrence rates.
Additionally, while Yi Chen has adjusted the 2025 revenue projections downward based on discussions with the company’s management, growth over 2024 is still anticipated. The valuation of Sensus Healthcare’s stock is supported by an EV/Revenue multiple and includes considerations of the company’s cash position. Despite potential risks such as market penetration challenges and competition, the positive clinical data and expected revenue growth underpin the Buy rating for Sensus Healthcare.
According to TipRanks, Chen is an analyst with an average return of -18.1% and a 26.95% success rate. Chen covers the Healthcare sector, focusing on stocks such as Opko Health, Vivani Medical, and Harrow Health.